ProMIS Working to Move Antibody Treatment for Alzheimer’s into Clinical Trials

ProMIS Working to Move Antibody Treatment for Alzheimer’s into Clinical Trials
ProMIS Neurosciences announced plans to initiate the development of its lead antibody candidate, PMN310, as a potential treatment for Alzheimer's disease. The investigational therapy is expected to enter clinical Phase 1 trials in 2019. PMN310 is a humanized antibody that attacks only toxic forms of the amyloid beta protein linked to Alzheimer's, not its normal forms. Preclinical studies involving both human brain cells in a lab and mice have shown that researchers should be able to increase doses of PMN310 in clinical trials without harming patien
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *